US · biotechnology · rna therapeutics
One round we have observed, with the investors the report named. Every figure below came from a named source, and where the company reported the raise to the SEC itself, that is shown beside it.
Series B · Jun 2026 · $100M
Viking Global Investors lead, Sofinnova Investments lead, Fidelity Management & Research Company, ARCH Venture Partners, Invus, Regeneron Ventures, Casdin Capital, NYBC Ventures, Rock Springs Capital
Reported by Ventureburn
Missing a round, or an investor who was in one? Tell us.